RNA biomarkers and molecular mechanisms provide insights into the pathogenesis of cardiomyopathy, aiming to augment phenotype-based management through customized medicine.
This review emphasizes the emerging role of RNA biomarkers in the pathogenesis and potential precision-guided management of cardiomyopathies.
Cardiomyopathy is a multifactorial cardiac disorder that results in structural and functional alterations in the heart due to molecular defects in the cardiomyocytes. It can manifest as hypertrophic, dilated, arrhythmogenic, or restrictive cardiomyopathies and affects around 1 in 500 persons globally. These conditions often lead to heart failure or sudden cardiac death. Sarcomeric and non-sarcomeric gene alterations have a well-established genetic foundation, but transcriptional and translational regulatory mechanisms, particularly those involving coding and non-coding RNAs, are becoming important factors in development and course of this disease. With a focus on RNA-mediated regulation and biomarker identification, this review incorporates molecular insights into the pathogenesis of cardiomyopathy. It aims to augment phenotype-based management through biomarker-driven, customized medicine for better diagnosis and targeted therapy, with emphasis on precision-guided approaches.
Kumar et al. (Tue,) conducted a review in Cardiomyopathy. RNA biomarkers was evaluated. RNA biomarkers and molecular mechanisms provide insights into the pathogenesis of cardiomyopathy, aiming to augment phenotype-based management through customized medicine.